Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma BLENREP DATA ANALYSIS

What's the purpose of this trial?

The purpose of this study is to describe the real-world use of Belantamab Mafodotin - blmf (BLENREP) and associated patterns of care, including dosing and dose modification, eye care specialist visits, associated healthcare utilization, and clinical outcomes in patients with relapsed and/or refractory multiple myeloma (RRMM) seen in the Duke Cancer Institute (DCI) clinics.

This trial is currently open and accepting patients.

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

* Age \> 18 years of age as of start of treatment with BLENREP
* Patients with a corresponding diagnosis code consistent with multiple myeloma seen at Duke.
* Patients with a record of treatment with BLENREP for RRMM between August 5, 2020 and July 17,2023.
* Patients having healthcare encounters at Duke Cancer Institute (DCI) for at least 1-month after start of Blenrep treatment.

Exclusion Criteria:

* Patients who were included in any clinical trial for BLENREP including expanded access clinical trials
* Age \> 89 years of age as of start of index therapy

Additional Trial Information

Observational Trial

Enrollment: 30 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

North Carolina

Duke Cancer Center Duke University Medical Center

Durham, NC

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message